Legend Biotech Future Growth
Future criteria checks 5/6
Legend Biotech is forecast to grow earnings and revenue by 69.6% and 35.6% per annum respectively. EPS is expected to grow by 75.6% per annum. Return on equity is forecast to be 19.3% in 3 years.
Key information
69.6%
Earnings growth rate
75.6%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | 35.6% |
Future return on equity | 19.3% |
Analyst coverage | Good |
Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
Legend Biotech: The Story Brightens
Dec 05Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking
Aug 01Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt
Jul 05Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio
May 13Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,548 | 150 | 204 | 213 | 14 |
12/31/2025 | 1,023 | -144 | -95 | -133 | 20 |
12/31/2024 | 615 | -278 | -351 | -117 | 19 |
9/30/2024 | 520 | -348 | -176 | -158 | N/A |
6/30/2024 | 456 | -285 | -165 | -143 | N/A |
3/31/2024 | 343 | -466 | -264 | -239 | N/A |
12/31/2023 | 285 | -518 | -416 | -393 | N/A |
9/30/2023 | 233 | -509 | -371 | -347 | N/A |
6/30/2023 | 165 | -532 | -378 | -359 | N/A |
3/31/2023 | 112 | -517 | -276 | -262 | N/A |
12/31/2022 | 117 | -446 | -224 | -201 | N/A |
9/30/2022 | 106 | -416 | -237 | -221 | N/A |
6/30/2022 | 96 | -457 | -221 | -194 | N/A |
3/31/2022 | 119 | -346 | -293 | -250 | N/A |
12/31/2021 | 69 | -404 | -244 | -198 | N/A |
9/30/2021 | 93 | -356 | -245 | -185 | N/A |
6/30/2021 | 89 | -297 | -259 | -205 | N/A |
3/31/2021 | 80 | -340 | -256 | -204 | N/A |
12/31/2020 | 75 | -266 | -253 | -223 | N/A |
9/30/2020 | 59 | -310 | -300 | -227 | N/A |
6/30/2020 | 64 | -271 | -209 | -143 | N/A |
3/31/2020 | 61 | -165 | -160 | -125 | N/A |
1/1/2020 | 62 | -102 | -110 | -83 | N/A |
12/31/2018 | 49 | -3 | 287 | 308 | N/A |
12/31/2017 | 24 | 9 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LEGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: LEGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LEGN is expected to become profitable in the next 3 years.
Revenue vs Market: LEGN's revenue (35.6% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: LEGN's revenue (35.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LEGN's Return on Equity is forecast to be low in 3 years time (19.3%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 04:32 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Legend Biotech Corporation is covered by 27 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ishan Majumdar | Baptista Research |
Huidong Wang | Barclays |
Konstantinos Biliouris | BMO Capital Markets Equity Research |